T-cell Lymphoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

A Phase Ib/II Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Intervention:   Drug: GFH009 Sponsor:   Zhejiang Genfleet Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
Condition:   Peripheral T Cell Lymphoma Intervention:   Genetic: 84-gene penal Sponsors:   Ruijin Hospital;   West China Hospital;   Shandong Provincial Hospital;   RenJi Hospital;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

A Phase Ib/II Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Intervention:   Drug: GFH009 Sponsor:   Zhejiang Genfleet Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
Condition:   Peripheral T Cell Lymphoma Intervention:   Genetic: 84-gene penal Sponsors:   Ruijin Hospital;   West China Hospital;   Shandong Provincial Hospital;   RenJi Hospital;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

A Phase Ib/II Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Intervention:   Drug: GFH009 Sponsor:   Zhejiang Genfleet Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
Condition:   Peripheral T Cell Lymphoma Intervention:   Genetic: 84-gene penal Sponsors:   Ruijin Hospital;   West China Hospital;   Shandong Provincial Hospital;   RenJi Hospital;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

A Phase Ib/II Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Intervention:   Drug: GFH009 Sponsor:   Zhejiang Genfleet Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
Condition:   Peripheral T Cell Lymphoma Intervention:   Genetic: 84-gene penal Sponsors:   Ruijin Hospital;   West China Hospital;   Shandong Provincial Hospital;   RenJi Hospital;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

A Phase Ib/II Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Intervention:   Drug: GFH009 Sponsor:   Zhejiang Genfleet Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
Condition:   Peripheral T Cell Lymphoma Intervention:   Genetic: 84-gene penal Sponsors:   Ruijin Hospital;   West China Hospital;   Shandong Provincial Hospital;   RenJi Hospital;   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;   Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

A Phase Ib/II Study of GFH009 Monotherapy in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition:   Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Intervention:   Drug: GFH009 Sponsor:   Zhejiang Genfleet Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2023 Category: Research Source Type: clinical trials

CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
Condition:   Newly Diagnosed Peripheral T-cell Lymphoma Intervention:   Drug: CMOP+Chidamide Sponsor:   The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2023 Category: Research Source Type: clinical trials